Profile data is unavailable for this security.
About the company
Alliance Pharma PLC is a United Kingdom-based international consumer healthcare company. The principal activity of the Company is to act as a holding company. The principal activity of the Company is the acquisition, marketing and distribution of consumer healthcare and pharmaceutical products. Its segments are strategic business units that represent different parts of the overall product portfolio, these being Consumer Healthcare brands and Prescription Medicines. Its Consumer Healthcare brands include Kelo-Cote franchise, Amberen, Nizoral, MacuShield, Aloclair, Vamousse, and other consumer healthcare brands. Its Prescription Medicines include Hydromol, Flamma Franchise, Forceval and other prescription medicines. Its products include Aloclair Plus Gel, Changmin, Fazol Cream, Hydromol Ointment, Kelo-Stretch Cream, and others. It holds the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are sold around the world in more than 100 countries.
- Revenue in GBP (TTM)167.42m
- Net income in GBP936.00k
- Incorporated2001
- Employees249.00
- LocationAlliance Pharma PLCAvonbridge House, Bath RoadCHIPPENHAM SN15 2BBUnited KingdomGBR
- Phone+44 124 946 6966
- Fax+44 124 946 6977
- Websitehttps://www.alliancepharmaceuticals.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genovis AB | 10.45m | 3.14m | 252.53m | 37.00 | 80.38 | 20.06 | 69.40 | 24.17 | 0.6482 | 0.6482 | 2.16 | 2.60 | 0.8217 | -- | -- | 3,813,214.00 | 24.71 | 11.86 | 27.23 | 14.22 | 69.44 | 61.79 | 30.08 | 14.30 | -- | -- | 0.00 | 0.00 | 10.07 | 34.96 | -54.84 | -- | 16.75 | -- |
| Selvita SA | 79.41m | 5.39m | 259.33m | 847.00 | 48.10 | 4.99 | 19.82 | 3.27 | 1.53 | 1.52 | 22.48 | 14.71 | 0.7731 | 23.99 | 5.51 | 464,081.90 | 5.49 | -- | 6.95 | -- | 66.57 | -- | 7.10 | -- | 1.31 | 9.90 | 0.4541 | -- | 31.71 | -- | 103.43 | -- | -- | -- |
| Niox Group PLC | 31.30m | 14.10m | 264.70m | 92.00 | 19.80 | 3.23 | 14.16 | 8.46 | 0.0318 | 0.0363 | 0.0707 | 0.1952 | 0.3386 | 2.68 | 5.05 | 340,217.40 | 15.25 | -7.42 | 16.49 | -9.21 | 70.93 | 74.04 | 45.05 | -44.46 | 2.97 | -- | 0.0121 | -- | 12.19 | -7.53 | 513.04 | -- | -34.02 | -- |
| DBV Technologies SA | 4.59m | -78.84m | 288.81m | 226.00 | -- | -- | -- | 62.92 | -1.67 | -1.67 | 0.0973 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,717.80 | -1,272.93 | -- | -586.89 | -- | -- | -49.38 | -10.69 | 38.59 | -- | -- | -- |
| Hyloris Pharmaceuticals SA | 2.54m | -9.28m | 291.83m | 24.00 | -- | 6.16 | -- | 114.81 | -0.3954 | -0.3954 | 0.1085 | 1.97 | 0.0471 | -- | 0.7924 | 125,042.40 | -17.19 | -22.99 | -20.60 | -29.15 | 96.81 | 92.55 | -364.96 | -644.94 | -- | -- | 0.0158 | -- | -4.68 | 69.17 | 6.99 | -- | -23.39 | -- |
| Ultimovacs ASA | 0.00 | -12.04m | 295.17m | 24.00 | -- | 9.58 | -- | -- | -4.82 | -4.82 | 0.00 | 12.30 | 0.00 | -- | -- | 0.00 | -30.14 | -25.92 | -32.89 | -27.77 | -- | -- | -- | -- | -- | -- | 0.0118 | -- | -- | -- | -1.86 | -- | 56.16 | -- |
| Avacta Group Plc | 9.65m | -39.54m | 305.64m | 133.00 | -- | 16.00 | -- | 31.66 | -0.1535 | -0.152 | 0.0378 | 0.0694 | 0.1382 | 2.58 | 1.95 | -- | -56.63 | -- | -116.86 | -- | 75.03 | -- | -409.61 | -- | 0.7967 | -2.51 | 0.7734 | -- | 228.22 | -- | -49.92 | -- | -- | -- |
| MedCap AB (publ) | 82.27m | 8.70m | 326.71m | 368.00 | 37.55 | 5.15 | 21.42 | 3.97 | 7.94 | 7.94 | 75.04 | 57.83 | 0.8552 | 3.71 | 7.23 | 3,019,565.00 | 9.08 | 7.70 | 11.51 | 10.71 | 47.81 | 45.26 | 10.62 | 8.46 | 1.92 | 8.99 | 0.2836 | 0.00 | 21.28 | -- | 21.87 | -- | -- | -- |
| Alliance Pharma plc | 167.42m | 936.00k | 327.32m | 249.00 | 417.93 | 1.14 | 27.99 | 1.96 | 0.0015 | 0.0015 | 0.3084 | 0.5327 | 0.3217 | 2.90 | 4.70 | 672,353.40 | 0.1798 | 2.64 | 0.1964 | 2.95 | 60.74 | 63.38 | 0.5591 | 8.35 | 1.73 | 5.37 | 0.3235 | 63.20 | 2.58 | 10.50 | -87.21 | -49.62 | -25.78 | 5.94 |
| Deva Holding AS | 211.65m | 54.98m | 347.77m | 2.92k | 6.33 | 2.09 | 5.73 | 1.64 | 7.27 | 7.27 | 27.98 | 22.04 | 0.7126 | 1.49 | 6.60 | 1,968,080.00 | 18.51 | 21.33 | 32.87 | 33.37 | 54.19 | 53.72 | 25.98 | 32.51 | 0.9247 | 15.28 | 0.4796 | 2.77 | 92.15 | 41.11 | 16.25 | 71.18 | 58.49 | -- |
| Philogen SpA | 20.43m | -4.63m | 382.87m | 141.00 | -- | 6.27 | -- | 18.74 | -0.1324 | -0.1324 | 0.5839 | 2.42 | 0.1834 | 6.03 | 11.98 | 168,177.30 | -4.16 | -6.14 | -4.55 | -7.26 | 59.07 | 34.41 | -22.67 | -50.97 | 9.00 | 0.1995 | 0.1387 | -- | 850.04 | 17.90 | 65.81 | -- | 52.53 | -- |
| Carbios SA | 60.30k | -23.90m | 387.55m | 104.00 | -- | 3.58 | -- | 6,427.58 | -2.47 | -2.47 | 0.0062 | 11.16 | 0.0004 | -- | 1.92 | 673.08 | -15.30 | -9.39 | -16.59 | -10.23 | -1,531.43 | -- | -39,630.00 | -1,258.36 | -- | -15.14 | 0.2338 | -- | -33.33 | -41.05 | -833.89 | -- | 99.37 | -- |
| Calliditas Therapeutics AB | 69.93m | -29.08m | 405.84m | 181.00 | -- | 8.38 | -- | 5.80 | -7.35 | -7.35 | 17.71 | 10.98 | 0.6029 | 3.55 | 16.30 | 9,259,775.00 | -25.07 | -27.85 | -29.58 | -30.95 | 97.50 | -- | -41.58 | -125.04 | 3.89 | -31.87 | 0.5589 | -- | 250.07 | -- | 17.59 | -- | -- | -- |
| Northern Data AG | 14.11m | -72.58m | 406.17m | 162.00 | -- | 1.64 | -- | 28.79 | -7.25 | -7.25 | 1.41 | 12.06 | -- | -- | -- | 101,094.80 | -- | 20.18 | -- | 33.16 | 37.20 | 50.93 | -514.48 | 85.77 | 0.301 | -0.5252 | 0.2519 | 0.00 | 1,059.28 | 485.60 | 440.81 | -- | -- | -- |
Data as of Jun 06 2023. Currency figures normalised to Alliance Pharma PLC's reporting currency: UK Pound GBX
45.73%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Slater Investments Ltd.as of 21 Mar 2022 | 49.69m | 9.20% |
| Van Lanschot Kempen Investment Management NVas of 21 Mar 2022 | 39.39m | 7.30% |
| BlackRock Investment Management (UK) Ltd.as of 28 Sep 2022 | 26.35m | 4.88% |
| Investec Wealth & Investment Ltd.as of 21 Mar 2022 | 24.83m | 4.60% |
| Fidelity Management & Research Co. LLCas of 12 Dec 2022 | 23.29m | 4.31% |
| Rathbones Investment Management Ltd.as of 21 Mar 2022 | 19.53m | 3.62% |
| Polar Capital LLPas of 21 Mar 2022 | 19.10m | 3.54% |
| RBC Global Asset Management (UK) Ltd.as of 08 Jun 2022 | 16.55m | 3.06% |
| Artemis Investment Management LLPas of 23 Mar 2021 | 16.30m | 3.02% |
| Janus Henderson Investors UK Ltd.as of 02 Mar 2023 | 11.91m | 2.21% |
More ▼
Data from 30 Sep 2022 - 28 Apr 2023Source: FactSet Research Systems Inc.
